Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Significant Drop in Short Interest

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 12,316 shares, a drop of 14.0% from the February 26th total of 14,323 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 86,687 shares, the days-to-cover ratio is currently 0.1 days.

Neuphoria Therapeutics Stock Performance

NEUP traded up $0.24 during mid-day trading on Tuesday, reaching $4.18. 24,158 shares of the stock were exchanged, compared to its average volume of 47,983. Neuphoria Therapeutics has a 1 year low of $3.64 and a 1 year high of $21.40. The stock has a market capitalization of $22.53 million, a PE ratio of -0.95 and a beta of 0.50. The company has a 50 day moving average price of $4.27 and a two-hundred day moving average price of $6.18.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its earnings results on Tuesday, February 17th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.21). Sell-side analysts expect that Neuphoria Therapeutics will post -1.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on NEUP shares. HC Wainwright lowered their target price on shares of Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, December 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. Finally, Zacks Research raised Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $21.00.

Hedge Funds Weigh In On Neuphoria Therapeutics

Hedge funds have recently modified their holdings of the company. Commonwealth Equity Services LLC purchased a new position in shares of Neuphoria Therapeutics in the 4th quarter worth approximately $43,000. XTX Topco Ltd purchased a new stake in shares of Neuphoria Therapeutics during the fourth quarter valued at approximately $47,000. Persistent Asset Partners Ltd lifted its holdings in Neuphoria Therapeutics by 173.1% during the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock worth $52,000 after acquiring an additional 8,495 shares during the period. Boothbay Fund Management LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter worth $54,000. Finally, Bridgeway Capital Management LLC purchased a new position in Neuphoria Therapeutics in the fourth quarter worth $57,000. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.